Pune's Serum Institute of India is placing its bets on the Oxford-AstraZeneca vaccine candidate AZD1222
Published On: Wednesday, July 22, 2020 | By: Team KnowMyStock
Oxford-AstraZeneca vaccine candidate AZD1222 being produced at Pune’s Serum Institute of India is most likely immunogenic and effective for mass use.CEO Adar Poonawalla stated that he would start manufacturing at personal risk. The company is investing $200 million in the vaccine facility and that he wants to keep the price at below Rs 1,000. I’m confident that the Oxford-AstraZeneca vaccine candidate will be immunogenic and effective for mass use. Once the trials are successful in India and the UK, we are certain that COVISHIELD will be one of the first vaccines to be introduced" Sri Poonawalla said.
"Phase-III clinical trials of the vaccine are expected to commence around August.Most vaccines are administered in two to three doses, in order to prime with the first dose and then boost immunity with the second. Similarly, I predict that the vaccines for Covid-19 will be administered in two doses" he added.According to Sri Adar Poonawala It is too early to comment on the pricing.
""However initially we would like to keep it under Rs 1,000. The government will be taking care of the distribution. We hope that people do not have to pay for the vaccine initially" he added.
We are on Telegram!
JOIN our telegram channel to receive updates on Financial News and Stock and FNO Tips.
Click Here!
Follow Us On:
